The ESMO TAT 2025 programme is online!
The development of novel anticancer agents can transform our understanding of malignancies and impact clinical care. The ESMO TAT Congress is dedicated to improving the conduct of early phase clinical trials in oncology by providing the latest scientific breakthroughs as well as workshops and educational reviews on pre-clinical and early clinical data.
Moreover, ESMO TAT 2025, as a unique multi-stakeholder Forum in the early drug development arena, will bring together investigators from academia, translational scientists, methodological experts and opinion leaders from industry, investor and regulatory bodies to highlight new data, promote collaboration and tackle challenges for accelerating the bench-to-bedside pathway to the benefit of our patients.
Learning objectives
In the Keynote lectures, Educational sessions, Special sessions with Industry, Workshops, Scientific sessions and Poster exhibition, attendees will be able to update their knowledge on:
- Innovation in phase I trials, including methods, design and endpoints
- Developments in preclinical modelling to support modern drug development
- Novel molecular imaging technologies
- Recent developments in cellular and gene-based therapies
- Early pipeline breakthroughs in novel kinase inhibitors, oral immunotherapies, next-generation macromolecules
- Methodological and regulatory challenges in the development of new agents
- Insights from the oncology early drug development and biotechnology industries
Audience
The ESMO TAT programme will be of interest to anyone in academia, industry, and regulatory agencies engaged in the discovery and early clinical development of novel anticancer therapies, including but not limited to preclinical scientists, clinicians, methodological experts, legal and regulatory affairs specialists, industry investigators and executives, other professionals active in anticancer drug development and patient advocates. The programme will be of educational value to oncologists, haematologists, pathologists, and organ system specialists wishing to familiarise themselves with emerging innovations in cancer therapy, while it has been enriched so as to provide a unique osmosis between academia and industry for the sake of sharing advances, challenges, and solutions that will accelerate development of novel therapeutics.
Accreditation
ESMO-MORA: The ESMO TAT 2025 Congress programme will be accredited with ESMO-MORA category 1 points. Recertification is necessary for medical oncologists to remain professionally certified by ESMO. It also guarantees that a certified medical oncologist has continued to update her/his knowledge and still possess the necessary skills and standards for the practice of medical oncology. See here for further details.
Disclaimer
ESMO is a scientific and professional, non-political and non-religious organisation. ESMO will not accept responsibility for any comments or remarks made during any of our events by session chairs, invited speakers, presenters, members or any other contributor, formally or informally, which might cause offence or be perceived as being biased.
The experts invited by ESMO as abstract Discussants are selected on an individual basis to provide their own interpretation of the data and are not acting as ESMO spokespersons.
All Speakers and Discussants are required to declare their interests, if any, and include a Declaration of Interest (DOI) slide at the start of their presentation(s).
The ESMO recommendations on the clinical utility of new drugs are only presented in the ESMO Clinical Practice Guidelines and such recommendations represent the only official position of ESMO.